Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID	DTD0456 Transporter Info
Gene Name	SLC6A4
Transporter Name	Sodium-dependent serotonin transporter
Gene ID	6532
UniProt ID	P31645

Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)
Chemical Compound
DT Modulation1	Cocaine binds to and results in decreased activity of SLC6A4 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Cocaine inhibits the reaction Serotonin results in increased activity of SLC6A4 protein			[81]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Cocaine inhibits the reaction SLC6A4 protein results in increased import of Biogenic Monoamines analog			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Cocaine inhibits the reaction SLC6A4 protein results in increased import of Fluorescent Dyes			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Cocaine inhibits the reaction SLC6A4 protein results in increased uptake of 4-(4-(dimethylamino)phenyl)-1-methylpyridinium			[81]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Cocaine results in decreased activity of SLC6A4 protein			[104]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Cocaine results in increased expression of SLC6A4 protein			[105]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Fluoxetine affects the expression of SLC6A4 protein			[109]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Fluoxetine binds to and results in decreased activity of SLC6A4 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Fluoxetine inhibits the reaction SLC6A4 protein results in increased import of Biogenic Monoamines analog			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Fluoxetine inhibits the reaction SLC6A4 protein results in increased import of Fluorescent Dyes			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Fluoxetine results in decreased localization of SLC6A4 protein			[110]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	SLC6A4 affects the susceptibility to Fluoxetine			[111]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	SLC6A4 gene polymorphism results in decreased susceptibility to Fluoxetine			[112]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	SLC6A4 gene polymorphism results in increased susceptibility to Fluoxetine			[113]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	SLC6A4 protein affects the susceptibility to Fluoxetine			[113]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	SLC6A4 protein results in increased susceptibility to Fluoxetine			[112]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Citalopram binds to and results in decreased activity of SLC6A4 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Citalopram inhibits the reaction convulxin promotes the reaction SLC6A4 protein binds to SYK protein			[99]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Citalopram inhibits the reaction SLC6A4 protein promotes the reaction Dopamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Citalopram inhibits the reaction SLC6A4 protein promotes the reaction Methamphetamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Citalopram inhibits the reaction SLC6A4 protein promotes the reaction Octopamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Citalopram inhibits the reaction SLC6A4 protein promotes the reaction tryptamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Citalopram inhibits the reaction SLC6A4 protein promotes the reaction Tyramine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	SLC6A4 polymorphism inhibits the reaction Citalopram affects the secretion of PRL protein			[101]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	SLC6A4 promoter polymorphism affects the susceptibility to Citalopram			[102]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Mazindol binds to and results in decreased activity of SLC6A4 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Paroxetine binds to and results in decreased activity of SLC6A4 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Paroxetine results in decreased expression of SLC6A4 mRNA			[121]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Amphetamine inhibits the reaction SLC6A4 protein results in increased import of Biogenic Monoamines analog			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Amphetamine inhibits the reaction SLC6A4 protein results in increased import of Fluorescent Dyes			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Citalopram inhibits the reaction SLC6A4 protein promotes the reaction Methamphetamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	indatraline inhibits the reaction SLC6A4 protein promotes the reaction Methamphetamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Methamphetamine results in decreased expression of SLC6A4 protein			[115]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	SLC6A4 protein promotes the reaction Methamphetamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	SLC6A4 gene polymorphism affects the susceptibility to Dextroamphetamine			[106]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Citalopram inhibits the reaction SLC6A4 protein promotes the reaction Dopamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	indatraline inhibits the reaction SLC6A4 protein promotes the reaction Dopamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A4 protein promotes the reaction Dopamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Aripiprazole binds to SLC6A4 protein			[92]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	SLC6A4 polymorphism affects the susceptibility to Bupropion			[96]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Clomipramine binds to and results in decreased activity of SLC6A4 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC6A4 polymorphism inhibits the reaction Clomipramine affects the secretion of PRL protein			[101]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Simvastatin results in increased activity of SLC6A4 protein			[50]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Lamivudine co-treated with IFNA2 protein results in increased expression of SLC6A4 mRNA			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Lamivudine promotes the reaction SLC6A4 protein results in increased uptake of Serotonin			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Lamivudine results in increased expression of and results in increased activity of SLC6A4 protein			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Ribavirin promotes the reaction SLC6A4 protein results in increased uptake of Serotonin			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Ribavirin results in increased expression of and results in increased activity of SLC6A4 protein			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Valproic Acid affects the expression of SLC6A4 mRNA			[128]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Sertraline binds to SLC6A4 protein			[124]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Sertraline inhibits the reaction Monocrotaline results in increased expression of SLC6A4 mRNA			[117]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A4 promoter polymorphism results in increased susceptibility to Sertraline			[125]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	SLC6A4 protein affects the susceptibility to Sertraline			[125]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Vortioxetine binds to and results in decreased activity of SLC6A4 protein			[130]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Vortioxetine results in decreased expression of SLC6A4 protein			[131]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	SLC6A4 gene polymorphism results in decreased susceptibility to Nortriptyline			[112]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC6A4 polymorphism affects the susceptibility to Nortriptyline			[96]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A4 promoter polymorphism affects the susceptibility to Nortriptyline			[119]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	SLC6A4 protein results in increased susceptibility to Nortriptyline			[112]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	SLC6A4 gene polymorphism results in decreased uptake of Serotonin which results in decreased susceptibility to Clozapine			[103]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC6A4 protein affects the susceptibility to Clozapine			[103]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	4-methylaminorex inhibits the reaction SLC6A4 protein results in increased uptake of Serotonin			[91]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Cocaine inhibits the reaction Serotonin results in increased activity of SLC6A4 protein			[81]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Lamivudine promotes the reaction SLC6A4 protein results in increased uptake of Serotonin			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Monensin promotes the reaction para-methyl-4-methylaminorex inhibits the reaction SLC6A4 protein results in increased uptake of Serotonin			[116]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC6A4 protein results in increased uptake of Serotonin			[116]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	para-methyl-4-methylaminorex inhibits the reaction SLC6A4 protein results in increased uptake of Serotonin			[116]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Ribavirin promotes the reaction SLC6A4 protein results in increased uptake of Serotonin			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Serotonin binds to SLC6A4 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	Serotonin results in increased activity of SLC6A4 protein			[81]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	SLC6A4 gene polymorphism affects the abundance of Serotonin			[123]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	SLC6A4 gene polymorphism results in decreased uptake of Serotonin which results in decreased susceptibility to Clozapine			[103]
Regulation Mechanism				Transcription Factor Info
DT Modulation12	SLC6A4 protein promotes the reaction Serotonin results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation13	SLC6A4 protein results in increased uptake of Serotonin			[51]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Benzo(a)pyrene results in decreased methylation of SLC6A4 promoter			[94]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Benzo(a)pyrene results in increased methylation of SLC6A4 5' UTR			[94]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Benzo(a)pyrene results in increased methylation of SLC6A4 exon			[94]
Regulation Mechanism				Transcription Factor Info
1-(4-methylphenyl)propane-2-amine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	1-(4-methylphenyl)propane-2-amine analog results in increased activity of SLC6A4 protein			[81]
Regulation Mechanism				Transcription Factor Info
2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction SLC6A4 protein results in increased import of Biogenic Monoamines analog			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction SLC6A4 protein results in increased import of Fluorescent Dyes			[88]
Regulation Mechanism				Transcription Factor Info
2,4,5,2',4',5'-hexachlorobiphenyl	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of SLC6A4 mRNA			[89]
Regulation Mechanism				Transcription Factor Info
2-(4-bromo-2,5-dimethoxyphenyl)ethylamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2-(4-bromo-2,5-dimethoxyphenyl)ethylamine inhibits the reaction SLC6A4 protein results in increased import of Biogenic Monoamines analog			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	2-(4-bromo-2,5-dimethoxyphenyl)ethylamine inhibits the reaction SLC6A4 protein results in increased import of Fluorescent Dyes			[88]
Regulation Mechanism				Transcription Factor Info
2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine inhibits the reaction SLC6A4 protein results in increased import of Biogenic Monoamines analog			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine inhibits the reaction SLC6A4 protein results in increased import of Fluorescent Dyes			[88]
Regulation Mechanism				Transcription Factor Info
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine inhibits the reaction SLC6A4 protein results in increased import of Biogenic Monoamines analog			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine inhibits the reaction SLC6A4 protein results in increased import of Fluorescent Dyes			[88]
Regulation Mechanism				Transcription Factor Info
2beta-carbomethoxy-3beta-(4-iodophenyl)tropane	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2beta-carbomethoxy-3beta-(4-iodophenyl)tropane binds to and results in decreased activity of SLC6A4 protein			[90]
Regulation Mechanism				Transcription Factor Info
4-fluoroamphetamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-fluoroamphetamine inhibits the reaction SLC6A4 protein results in increased import of Biogenic Monoamines analog			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	4-fluoroamphetamine inhibits the reaction SLC6A4 protein results in increased import of Fluorescent Dyes			[88]
Regulation Mechanism				Transcription Factor Info
4-methoxymethamphetamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-methoxymethamphetamine inhibits the reaction SLC6A4 protein results in increased import of Biogenic Monoamines analog			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	4-methoxymethamphetamine inhibits the reaction SLC6A4 protein results in increased import of Fluorescent Dyes			[88]
Regulation Mechanism				Transcription Factor Info
4-methylaminorex	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-methylaminorex inhibits the reaction SLC6A4 protein results in increased uptake of Serotonin			[91]
Regulation Mechanism				Transcription Factor Info
5-(2-aminopropyl)benzofuran	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	5-(2-aminopropyl)benzofuran inhibits the reaction SLC6A4 protein results in increased import of Biogenic Monoamines analog			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	5-(2-aminopropyl)benzofuran inhibits the reaction SLC6A4 protein results in increased import of Fluorescent Dyes			[88]
Regulation Mechanism				Transcription Factor Info
ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate results in decreased expression of SLC6A4 mRNA			[79]
Regulation Mechanism				Transcription Factor Info
aristolochic acid I	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	aristolochic acid I results in increased expression of SLC6A4 mRNA			[93]
Regulation Mechanism				Transcription Factor Info
bisphenol A	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol A co-treated with Fulvestrant results in decreased methylation of SLC6A4 gene			[95]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	bisphenol A results in decreased expression of SLC6A4 mRNA			[56]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	bisphenol A results in increased expression of SLC6A4 mRNA			[89]
Regulation Mechanism				Transcription Factor Info
bisphenol AF	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol AF results in decreased expression of SLC6A4 mRNA			[56]
Regulation Mechanism				Transcription Factor Info
bisphenol S	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol S results in decreased expression of SLC6A4 mRNA			[56]
Regulation Mechanism				Transcription Factor Info
Cannabidiol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cannabidiol results in decreased expression of SLC6A4 mRNA			[97]
Regulation Mechanism				Transcription Factor Info
CGP 52608	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	CGP 52608 promotes the reaction RORA protein binds to SLC6A4 gene			[98]
Regulation Mechanism				Transcription Factor Info
Colchicine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Colchicine results in decreased expression of SLC6A4 mRNA			[56]
Regulation Mechanism				Transcription Factor Info
di-n-butylphosphoric acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	di-n-butylphosphoric acid affects the expression of SLC6A4 mRNA			[107]
Regulation Mechanism				Transcription Factor Info
ethyl-p-hydroxybenzoate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	ethyl-p-hydroxybenzoate results in increased expression of SLC6A4 mRNA			[108]
Regulation Mechanism				Transcription Factor Info
Fulvestrant	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol A co-treated with Fulvestrant results in decreased methylation of SLC6A4 gene			[95]
Regulation Mechanism				Transcription Factor Info
indatraline	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	indatraline inhibits the reaction SLC6A4 protein promotes the reaction Dopamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	indatraline inhibits the reaction SLC6A4 protein promotes the reaction Methamphetamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	indatraline inhibits the reaction SLC6A4 protein promotes the reaction Octopamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	indatraline inhibits the reaction SLC6A4 protein promotes the reaction tryptamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	indatraline inhibits the reaction SLC6A4 protein promotes the reaction Tyramine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
methyleugenol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	methyleugenol results in decreased expression of SLC6A4 mRNA			[78]
Regulation Mechanism				Transcription Factor Info
Monensin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Monensin promotes the reaction para-methyl-4-methylaminorex inhibits the reaction SLC6A4 protein results in increased uptake of Serotonin			[116]
Regulation Mechanism				Transcription Factor Info
Monocrotaline	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Monocrotaline results in increased expression of SLC6A4 mRNA			[117]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Sertraline inhibits the reaction Monocrotaline results in increased expression of SLC6A4 mRNA			[117]
Regulation Mechanism				Transcription Factor Info
nisoxetine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	nisoxetine binds to and results in decreased activity of SLC6A4 protein			[90]
Regulation Mechanism				Transcription Factor Info
N-Methyl-3,4-methylenedioxyamphetamine	8 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	N-Methyl-3,4-methylenedioxyamphetamine affects the expression of SLC6A4 protein			[118]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	N-Methyl-3,4-methylenedioxyamphetamine affects the reaction N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine binds to SLC6A4 protein			[118]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	N-Methyl-3,4-methylenedioxyamphetamine binds to SLC6A4 protein			[90]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC6A4 protein results in increased import of Biogenic Monoamines analog			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC6A4 protein results in increased import of Fluorescent Dyes			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction SLC6A4 protein results in increased uptake of Serotonin			[116]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	N-Methyl-3,4-methylenedioxyamphetamine results in decreased activity of SLC6A4 protein			[91]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of SLC6A4 protein			[71]
Regulation Mechanism				Transcription Factor Info
N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	N-Methyl-3,4-methylenedioxyamphetamine affects the reaction N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine binds to SLC6A4 protein			[118]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine binds to SLC6A4 protein			[118]
Regulation Mechanism				Transcription Factor Info
N-Nitrosopyrrolidine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	N-Nitrosopyrrolidine results in decreased expression of SLC6A4 mRNA			[78]
Regulation Mechanism				Transcription Factor Info
Nomifensine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Nomifensine binds to and results in decreased activity of SLC6A4 protein			[90]
Regulation Mechanism				Transcription Factor Info
Norepinephrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A4 protein promotes the reaction Norepinephrine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
Octopamine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Citalopram inhibits the reaction SLC6A4 protein promotes the reaction Octopamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	indatraline inhibits the reaction SLC6A4 protein promotes the reaction Octopamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A4 protein promotes the reaction Octopamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
Okadaic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Okadaic Acid results in decreased expression of SLC6A4 mRNA			[120]
Regulation Mechanism				Transcription Factor Info
para-methyl-4-methylaminorex	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Monensin promotes the reaction para-methyl-4-methylaminorex inhibits the reaction SLC6A4 protein results in increased uptake of Serotonin			[116]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	para-methyl-4-methylaminorex binds to SLC6A4 protein			[116]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	para-methyl-4-methylaminorex inhibits the reaction SLC6A4 protein results in increased uptake of Serotonin			[116]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	para-methyl-4-methylaminorex results in decreased activity of SLC6A4 protein			[91]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	SLC6A4 protein results in increased uptake of para-methyl-4-methylaminorex			[91]
Regulation Mechanism				Transcription Factor Info
perfluorooctane sulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	perfluorooctane sulfonic acid results in decreased expression of SLC6A4 mRNA			[79]
Regulation Mechanism				Transcription Factor Info
perfluorooctanoic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	perfluorooctanoic acid results in decreased expression of SLC6A4 mRNA			[79]
Regulation Mechanism				Transcription Factor Info
phenethylamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A4 protein promotes the reaction phenethylamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
Pyrilamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pyrilamine analog binds to SLC6A4 protein			[122]
Regulation Mechanism				Transcription Factor Info
sodium arsenite	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	sodium arsenite results in increased expression of SLC6A4 mRNA			[126]
Regulation Mechanism				Transcription Factor Info
theaflavin-3,3'-digallate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	theaflavin-3,3'-digallate affects the expression of SLC6A4 mRNA			[127]
Regulation Mechanism				Transcription Factor Info
tianeptine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	tianeptine binds to and results in decreased activity of SLC6A4 protein			[90]
Regulation Mechanism				Transcription Factor Info
triphenyl phosphate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	triphenyl phosphate affects the expression of SLC6A4 mRNA			[107]
Regulation Mechanism				Transcription Factor Info
tryptamine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Citalopram inhibits the reaction SLC6A4 protein promotes the reaction tryptamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	indatraline inhibits the reaction SLC6A4 protein promotes the reaction tryptamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A4 protein promotes the reaction tryptamine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
Tyramine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Citalopram inhibits the reaction SLC6A4 protein promotes the reaction Tyramine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	indatraline inhibits the reaction SLC6A4 protein promotes the reaction Tyramine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC6A4 protein promotes the reaction Tyramine results in increased activity of TAAR1 protein			[100]
Regulation Mechanism				Transcription Factor Info
Venlafaxine Hydrochloride	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A4 gene polymorphism affects the susceptibility to Venlafaxine Hydrochloride			[129]
Regulation Mechanism				Transcription Factor Info
Approved Drug
Cocaine	13 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cocaine inhibits the transportation of Mazindol by SLC6A4			[1]
Affected Drug/Substrate	Mazindol	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation2	Cocaine inhibits the transportation of RTI-55 by SLC6A4			[1], [2]
Affected Drug/Substrate	RTI-55	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation3	Cocaine inhibits the transportation of Serotonin by SLC6A4			[3]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)1-SERT
DT Modulation4	Cocaine inhibits the transportation of Serotonin by SLC6A4			[4]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation5	Cocaine inhibits the activity of SLC6A4			[5], [6]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation6	Cocaine inhibits the activity of SLC6A4			[3]
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)1-SERT
Fluoxetine	15 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fluoxetine inhibits the transportation of Neurotransmitter by SLC6A4			[7]
Affected Drug/Substrate	Neurotransmitter	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation2	Fluoxetine inhibits the transportation of Serotonin by SLC6A4			[8]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)7-SERT
DT Modulation3	Fluoxetine inhibits the transportation of Serotonin by SLC6A4			[4], [11], [12]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation4	Fluoxetine inhibits the activity of SLC6A4			[16], [17], [18]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation5	Fluoxetine modulates the activity of SLC6A4			[19]
Citalopram	14 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Citalopram inhibits the transportation of Serotonin by SLC6A4			[8], [9]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)7-SERT
DT Modulation2	Citalopram inhibits the transportation of Serotonin by SLC6A4			[10]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation3	Citalopram inhibits the transportation of RTI-55 by SLC6A4			[13]
Affected Drug/Substrate	RTI-55	Modulation Type	Inhibition
DT Modulation4	Citalopram inhibits the activity of SLC6A4			[14], [15]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation5	Citalopram modulates the activity of SLC6A4			[19]
Reboxetine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Reboxetine inhibits the transportation of Citalopram by SLC6A4			[20], [21]
Affected Drug/Substrate	Citalopram	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation2	Reboxetine inhibits the transportation of RTI-55 by SLC6A4			[13]
Affected Drug/Substrate	RTI-55	Modulation Type	Inhibition
DT Modulation3	Reboxetine inhibits the activity of SLC6A4			[29]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Duloxetine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Duloxetine inhibits the transportation of Citalopram by SLC6A4			[21]
Affected Drug/Substrate	Citalopram	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation2	Duloxetine inhibits the transportation of Paroxetine by SLC6A4			[25]
Affected Drug/Substrate	Paroxetine	Modulation Type	Inhibition
DT Modulation3	Duloxetine inhibits the activity of SLC6A4			[26], [27], [28]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Mazindol	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Mazindol inhibits the transportation of Mazindol by SLC6A4			[1]
Affected Drug/Substrate	Mazindol	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation2	Mazindol inhibits the transportation of RTI-55 by SLC6A4			[1]
Affected Drug/Substrate	RTI-55	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation3	Mazindol inhibits the activity of SLC6A4			[5]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Venlafaxine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Venlafaxine inhibits the transportation of Neurotransmitter by SLC6A4			[7]
Affected Drug/Substrate	Neurotransmitter	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation2	Venlafaxine inhibits the transportation of Serotonin by SLC6A4			[4], [12]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation3	Venlafaxine inhibits the activity of SLC6A4			[28]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Escitalopram	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Escitalopram inhibits the transportation of Serotonin by SLC6A4			[22]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)7-SERT
DT Modulation2	Escitalopram inhibits the transportation of Serotonin by SLC6A4			[23]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation3	Escitalopram inhibits the activity of SLC6A4			[30]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Imipramine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Imipramine inhibits the transportation of Serotonin by SLC6A4			[24]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation2	Imipramine inhibits the activity of SLC6A4			[31], [32]
Cell System	Chinese hamster ovary (CHO) cells-SERT
DT Modulation3	Imipramine inhibits the activity of SLC6A4			[33]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Amitriptyline	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amitriptyline inhibits the transportation of Serotonin by SLC6A4			[4]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation2	Amitriptyline inhibits the activity of SLC6A4			[36], [37], [38]
Ziprasidone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ziprasidone inhibits the activity of SLC6A4			[34]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation2	Ziprasidone inhibits the activity of SLC6A4			[35]
Cell System	Chinese hamster ovary (CHO) cells-SERT
Paroxetine	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Paroxetine inhibits the activity of SLC6A4			[14], [15], [33]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation2	Paroxetine modulates the activity of SLC6A4			[19]
Desvenlafaxine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Desvenlafaxine inhibits the activity of SLC6A4			[28]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
DT Modulation2	Desvenlafaxine modulates the activity of SLC6A4			[41]
Fluvoxamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fluvoxamine inhibits the activity of SLC6A4			[39], [40]
DT Modulation2	Fluvoxamine modulates the activity of SLC6A4			[43]
Vilazodone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Vilazodone modulates the activity of SLC6A4			[42]
DT Modulation2	Vilazodone inhibits the activity of SLC6A4			[44]
4-Fluoroamphetamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-Fluoroamphetamine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 19 microM)			[45]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
4-Fluoromethamphetamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-Fluoromethamphetamine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 8.7 microM)			[45]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Amphetamine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amphetamine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 45 microM)			[45]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Ephedrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ephedrine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 230 microM)			[45]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Methamphetamine	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methamphetamine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 18 microM)			[45]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Dextroamphetamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dextroamphetamine inhibits the transportation of Serotonin by SLC6A4			[4]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Modafinil	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Modafinil inhibits the transportation of Serotonin by SLC6A4			[46]
Affected Drug/Substrate	Serotonin	Modulation Type	Inhibition
Cell System	Monkey kidney tissue Fibroblast-like cell lines (COS)7-SERT
Dopamine	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dopamine inhibits the activity of SLC6A4			[47]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Methylphenidate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methylphenidate inhibits the activity of SLC6A4			[48]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Aripiprazole	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Aripiprazole inhibits the activity of SLC6A4			[34]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Chlorpromazine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Chlorpromazine inhibits the activity of SLC6A4			[34]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Bupropion	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bupropion inhibits the activity of SLC6A4			[6]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Moclobemide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Moclobemide inhibits the activity of SLC6A4			[35]
Cell System	Chinese hamster ovary (CHO) cells-SERT
Pimozide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pimozide inhibits the activity of SLC6A4			[35]
Cell System	Chinese hamster ovary (CHO) cells-SERT
Risperidone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Risperidone inhibits the activity of SLC6A4			[35]
Cell System	Chinese hamster ovary (CHO) cells-SERT
Clomipramine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Clomipramine inhibits the activity of SLC6A4			[49]
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Simvastatin	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Simvastatin increases the activity of SLC6A4			[50]
Lamivudine	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Lamivudine increases the expression of SLC6A4			[51]
Ribavirin	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ribavirin increases the expression of SLC6A4			[51]
Copper Sulfate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Copper Sulfate inhibits the expression of SLC6A4			[52]
Hydrogen Peroxide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Hydrogen Peroxide affects the expression of SLC6A4			[53]
Cyclosporine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cyclosporine inhibits the expression of SLC6A4			[54]
Urethane	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Urethane inhibits the expression of SLC6A4			[55]
Estradiol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Estradiol inhibits the expression of SLC6A4			[56]
Gabapentin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Gabapentin inhibits the expression of SLC6A4			[56]
Hydroxyurea	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Hydroxyurea inhibits the expression of SLC6A4			[56]
Sulfadiazine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sulfadiazine inhibits the expression of SLC6A4			[56]
Valproic Acid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Valproic Acid inhibits the expression of SLC6A4			[56]
Amfepramone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amfepramone inhibits the activity of SLC6A4			[57], [58]
Sertraline	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sertraline inhibits the activity of SLC6A4			[59], [60]
Vortioxetine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Vortioxetine inhibits the activity of SLC6A4			[61], [62], [63]
Dextromethorphan polistirex	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dextromethorphan polistirex modulates the activity of SLC6A4			[19]
Nortriptyline	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Nortriptyline modulates the activity of SLC6A4			[19]
Sibutramine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sibutramine modulates the activity of SLC6A4			[19]
Trazodone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Trazodone modulates the activity of SLC6A4			[19]
Chlorphentermine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Chlorphentermine modulates the activity of SLC6A4			[64]
Acetaminophen	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acetaminophen inhibits the activity of SLC6A4			[65]
Tianeptine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tianeptine inhibits the activity of SLC6A4			[66]
Levomilnacipran	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Levomilnacipran modulates the activity of SLC6A4			[67]
Clozapine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Clozapine inhibits the activity of SLC6A4			[68]
Olanzapine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Olanzapine inhibits the activity of SLC6A4			[68]
Quetiapine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Quetiapine inhibits the activity of SLC6A4			[68]
Haloperidol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Haloperidol inhibits the activity of SLC6A4			[68], [69]
Scopolamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Scopolamine induces the activity of SLC6A4			[70]
Drug in Phase 3 Trial
Pridopidine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pridopidine inhibits the activity of SLC6A4			[35]
Cell System	Chinese hamster ovary (CHO) cells-SERT
Triclosan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Triclosan inhibits the expression of SLC6A4			[77]
Dasotraline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dasotraline inhibits the activity of SLC6A4			[82]
Litoxetine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Litoxetine modulates the activity of SLC6A4			[83]
Bicifadine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bicifadine modulates the activity of SLC6A4			[84]
Amitifadine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amitifadine inhibits the activity of SLC6A4			[85], [86], [87]
Drug in Phase 2 Trial
Bisphenol A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bisphenol A inhibits the expression of SLC6A4			[56]
Drug in Phase 1 Trial
CCRIS-9277	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	CCRIS-9277 inhibits the expression of SLC6A4			[71]
Quercetin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Quercetin inhibits the expression of SLC6A4			[72]
Investigative Drug
3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	3',4'-Methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP) inhibits the transportation of Dopamine by SLC6A4 (IC50 = 15 microM)			[45]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP) inhibits the transportation of Dopamine by SLC6A4 (IC50 = 75 microM)			[45]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Methcathinone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methcathinone inhibits the transportation of Dopamine by SLC6A4 (IC50 = 46 microM)			[45]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Methylenedioxypyrovalerone (MDPV)	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methylenedioxypyrovalerone (MDPV) inhibits the transportation of Dopamine by SLC6A4 (IC50 = 9.6 microM)			[45]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Pyrovalerone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pyrovalerone inhibits the transportation of Dopamine by SLC6A4 (IC50 = 23 microM)			[45]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Serotonin	14 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Serotonin increases the activity of SLC6A4			[81]
Patented Pharmaceutical Agent
GSK-J4	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	GSK-J4 increases the expression of SLC6A4			[76]
Drug Withdrawn
Naphyrone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Naphyrone inhibits the transportation of Dopamine by SLC6A4 (IC50 = 0.8 microM)			[45]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Natural Product
4-Fluoroephedrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-Fluoroephedrine inhibits the transportation of Dopamine by SLC6A4 (IC50 = 134 microM)			[45]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-SERT
Particulate Matter	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Particulate Matter inhibits the expression of SLC6A4			[74]
Methyleugenol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methyleugenol inhibits the expression of SLC6A4			[78]
Tobacco Smoke Pollution	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tobacco Smoke Pollution increases the expression of SLC6A4			[80]
Environmental toxicant
Glyphosate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Glyphosate inhibits the expression of SLC6A4			[56]
Mercury	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC6A4 promoter polymorphism affects the susceptibility to Mercury			[114]
Regulation Mechanism				Transcription Factor Info
Mycotoxins
Aflatoxin B1	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Aflatoxin B1 inhibits the expression of SLC6A4			[56]
Fumonisin B1	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fumonisin B1 inhibits the expression of SLC6A4			[56]
fumonisin B1	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	fumonisin B1 results in decreased expression of SLC6A4 mRNA			[56]
Regulation Mechanism				Transcription Factor Info
ochratoxin A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	ochratoxin A results in decreased expression of SLC6A4 mRNA			[56]
Regulation Mechanism				Transcription Factor Info
Acute Toxic Substance
Formaldehyde	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Formaldehyde inhibits the expression of SLC6A4			[75]
Ochratoxin A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ochratoxin A inhibits the expression of SLC6A4			[56]
Carcinogen
Benzo(a)pyrene	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Benzo(a)pyrene inhibits the expression of SLC6A4			[78]
Cadmium	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cadmium binds to SLC6A4 protein mutant form			[90]
Regulation Mechanism				Transcription Factor Info
Health and Environmental Toxicant
tris(1,3-dichloro-2-propyl)phosphate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC6A4			[73]
Perfluorooctane sulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Perfluorooctane sulfonic acid inhibits the expression of SLC6A4			[79]
Lithium Chloride	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Lithium Chloride inhibits the expression of SLC6A4			[56]

References
1	Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters. J Med Chem. 2017 Apr 13;60(7):3109-3123.
2	Design, synthesis, and biological evaluation of novel non-piperazine analogues of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines as dopamine transporter inhibitors. J Med Chem. 1999 Sep 9;42(18):3647-56.
3	Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters. Bioorg Med Chem. 2007 Jun 15;15(12):4159-74.
4	An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3411-5.
5	Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter. J Med Chem. 2002 Sep 12;45(19):4097-109.
6	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
7	Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3--Oxyazetidine. ACS Med Chem Lett. 2014 Jul 10;5(9):999-1004.
8	From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies. J Med Chem. 2008 May 22;51(10):3045-8.
9	A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter. Bioorg Med Chem Lett. 2013 Jan 1;23(1):323-6.
10	Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents. Bioorg Med Chem. 2011 Feb 1;19(3):1328-48.
11	Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors. Bioorg Med Chem Lett. 2013 Oct 15;23(20):5515-8.
12	Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors. Bioorg Med Chem Lett. 2014 Aug 1;24(15):3234-7.
13	Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter. J Med Chem. 2004 Feb 26;47(5):1122-35.
14	Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter. Bioorg Med Chem. 2008 Jun 15;16(12):6364-70.
15	3-(4-(6-Fluoroalkoxy-3,4-dihydroisoquinoline-2(1H)-yl)cyclohexyl)-1H-indole-5-carbonitriles for SERT imaging: chemical synthesis, evaluation in vitro and radiofluorination. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4727-30.
16	Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
17	Dual inhibitors of phosphodiesterase-4 and serotonin reuptake. J Med Chem. 2009 Mar 26;52(6):1530-9.
18	Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1834-8.
19	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
20	[4-(Phenoxy)pyridin-3-yl]methylamines: a new class of selective noradrenaline reuptake inhibitors. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1795-8.
21	Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2562-6.
22	Novel and high affinity fluorescent ligands for the serotonin transporter based on (s)-citalopram. ACS Med Chem Lett. 2014 Mar 27;5(6):696-9.
23	Novel Azido-Iodo Photoaffinity Ligands for the Human Serotonin Transporter Based on the Selective Serotonin Reuptake Inhibitor (S)-Citalopram. J Med Chem. 2015 Jul 23;58(14):5609-19.
24	Synthesis and inhibitory evaluation of 3-linked imipramines for the exploration of the S2 site of the human serotonin transporter. Bioorg Med Chem. 2016 Jun 15;24(12):2725-38.
25	Synthesis and biological activity of some known and putative duloxetine metabolites. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3481-6.
26	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
27	N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5078-81.
28	Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor. ACS Med Chem Lett. 2013 May 7;4(6):560-4.
29	Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging of the norepinephrine transporter. J Med Chem. 2009 Jan 8;52(1):62-73.
30	Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5552-5.
31	Novel arylsulfonamide derivatives with 5-HT6/5-HT7 receptor antagonism targeting behavioral and psychological symptoms of dementia. J Med Chem. 2014 Jun 12;57(11):4543-57.
32	Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia. Eur J Med Chem. 2015 Mar 6;92:221-35.
33	Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT 1A weak partial agonistic activity showing the antidepressant-like effect. Bioorg Med Chem. 2017 Jan 1;25(1):293-304.
34	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. J Med Chem. 2007 Oct 18;50(21):5103-8.
35	Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach. J Med Chem. 2012 Nov 26;55(22):9735-50.
36	Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
37	A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):285-90.
38	The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds. Bioorg Med Chem Lett. 2014 Jan 15;24(2):576-9.
39	Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine. Yonsei Med J. 2009 Jun 30;50(3):441-4.
40	Placebo controlled double-blind trial of fluvoxamine maleate in the obese. J Psychosom Res. 1986;30(2):143-6.
41	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
42	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
43	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
44	Benzothiazoles as probes for the 5HT1A receptor and the serotonin transporter (SERT): a search for new dual-acting agents as potential antidepressants. Eur J Med Chem. 2012 Jul;53:124-32.
45	Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol. 2015 Mar;25(3):365-76.
46	Elucidation of structural elements for selectivity across monoamine transporters: novel 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues. J Med Chem. 2014 Feb 13;57(3):1000-13.
47	Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes. Bioorg Med Chem Lett. 2003 Nov 17;13(22):4133-7.
48	Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32.
49	Reengineered tricyclic anti-cancer agents. Bioorg Med Chem. 2015 Oct 1;23(19):6528-34.
50	Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res. 2005 Feb 28;133(2-3):197-203.
51	Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Scand J Immunol. 2006 Feb;63(2):106-15.
52	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
53	Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203.
54	Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
55	Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
56	Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18.
57	Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
58	Phentermine and anaesthesia. Anaesth Intensive Care. 2005 Aug;33(4):525-7.
59	Methadone: from pharmacokinetic profile to clinical pharmacology. Encephale. 2006 Jul-Aug;32(4 Pt 1):478-86.
60	Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
61	A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012 Jun;15(5):589-600.
62	Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013 Apr;105:41-50.
63	2013 FDA drug approvals. Nat Rev Drug Discov. 2014 Feb;13(2):85-9.
64	Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates.Implications for primary pulmonary hypertension.Circulation.1999 Aug 24;100(8):869-75.
65	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Jun 11.
66	Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39.
67	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
68	Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. Bioorg Med Chem. 2008 Aug 1;16(15):7291-301.
69	Further evaluation of the tropane analogs of haloperidol. Bioorg Med Chem Lett. 2014 Sep 1;24(17):4294-7.
70	BDNF mediates the protective effects of scopolamine in reserpine-induced depression-like behaviors via up-regulation of 5-HTT and TPH1. Psychiatry Res. 2019 Jan;271:328-334.
71	Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl). 2008 Oct;200(3):439-50.
72	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
73	Defensive and adverse energy-related molecular responses precede tris (1, 3-dichloro-2-propyl) phosphate cytotoxicity. J Appl Toxicol. 2016 May;36(5):649-58.
74	Redox/methylation mediated abnormal DNA methylation as regulators of ambient fine particulate matter-induced neurodevelopment related impairment in human neuronal cells. Sci Rep. 2016 Sep 14;6:33402.
75	Cellular reactions to long-term volatile organic compound (VOC) exposures. Sci Rep. 2016 Dec 1;6:37842.
76	Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. J Biol Chem. 2018 Feb 16;293(7):2422-2437.
77	Transcriptome and DNA Methylome Dynamics during Triclosan-Induced Cardiomyocyte Differentiation Toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
78	Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
79	An assessment of serum-dependent impacts on intracellular accumulation and genomic response of per- and polyfluoroalkyl substances in a placental trophoblast model. Environ Toxicol. 2020 Dec;35(12):1395-1405.
80	Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Arch Toxicol. 2021 May;95(5):1739-1761.
81	Functional characterization of N-octyl 4-methylamphetamine variants and related bivalent compounds at the dopamine and serotonin transporters using Ca2+ channels as sensors. Toxicol Appl Pharmacol. 2021 May 15;419:115513.
82	Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
83	Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45.
84	Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine
85	Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 928).
86	1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors. J Med Chem. 2010 Mar 25;53(6):2534-51.
87	6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001.
88	Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay. Toxicol In Vitro. 2017;45(Pt 1):60-71.
89	Cultured human peripheral blood mononuclear cells alter their gene expression when challenged with endocrine-disrupting chemicals. Toxicology. 2013 Jan 7;303:17-24.
90	Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J Biol Chem. 2006;281(4):2012-23.
91	Pharmacological characterization of the aminorex analogs 4-MAR, 4,4'-DMAR, and 3,4-DMAR. Neurotoxicology. 2019 May;72:95-100.
92	Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter. J Med Chem. 2011;54(18):6305-18.
93	Integration of transcriptomic, proteomic and metabolomic data to reveal the biological mechanisms of AAI injury in renal epithelial cells. Toxicol In Vitro. 2021;70:105054.
94	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017;8(1):1369-1391.
95	DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019;11(1):138.
96	Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation. Addiction. 2012 Jan;107(1):178-87.
97	Cannabidiol disrupts tryptophan metabolism in the human term placenta. Toxicology. 2024;505:153813.
98	Identification of potential target genes of ROR-alpha in THP1 and HUVEC cell lines. Exp Cell Res. 2017;353(1):6-15.
99	Micromolar concentrations of citalopram or escitalopram inhibit glycoprotein VI-mediated and integrin IIb3-mediated signaling in human platelets. Toxicol Appl Pharmacol. 2019;364:106-113.
100	Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. J Pharmacol Exp Ther. 2007;321(1):116-27.
101	Polymorphism in the serotonin transporter gene and moderators of prolactin response to meta-chlorophenylpiperazine in African-American cocaine abusers and controls. Psychiatry Res. 2006;144(2-3):99-108.
102	5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol. 2003;23(6):563-7.
103	Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics. J Psychiatr Res. 2010 Dec;44(16):1158-62.
104	Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. J Psychiatr Res. 2008;42(14):1213-9.
105	Serotonin transporters upregulate with chronic cocaine use. J Chem Neuroanat. 2000;20(3-4):271-80.
106	Serotonin transporter genotype and acute subjective response to amphetamine. Am J Addict. 2006;15(5):327-35.
107	Association between Organophosphate Ester Exposure and Insulin Resistance with Glycometabolic Disorders among Older Chinese Adults 60-69 Years of Age: Evidence from the China BAPE Study. Environ Health Perspect. 2023;131(4):47009.
108	Risk assessment of parabens in a transcriptomics-based in vitro test. Chem Biol Interact. 2023;384:110699.
109	Fluoxetine-induced alterations in human platelet serotonin transporter expression: serotonin transporter polymorphism effects. J Psychiatry Neurosci. 2006;31(5):333-9.
110	Effect of long-term fluoxetine treatment on the human serotonin transporter in Caco-2 cells. Life Sci. 2007;80(16):1517-24.
111	Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry. 2003;54(9):879-83.
112	Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol. 2003;6(4):339-46.
113	Fluoxetine response in impulsive-aggressive behavior and serotonin transporter polymorphism in personality disorder. Psychiatr Genet. 2010;20(1):25-30.
114	The association between serotonin transporter gene promotor polymorphism (5-HTTLPR) and elemental mercury exposure on mood and behavior in humans. J Toxicol Environ Health A. 2010;73(15):1003-20.
115	Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry. 2006;63(1):90-100.
116	The psychostimulant ()-cis-4,4'-dimethylaminorex (4,4'-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters. Neuropharmacology. 2018;138:282-291.
117	Sertraline protects against monocrotaline-induced pulmonary hypertension in rats. Clin Exp Pharmacol Physiol. 2006;33(11):1047-51.
118	Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain. 2010;133(Pt 6):1779-97.
119	Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA. 2006 Oct 04;296(13):1609-18.
120	A multi-omics approach to elucidate okadaic acid-induced changes in human HepaRG hepatocarcinoma cells. Arch Toxicol. 2024;98(9):2919-2935.
121	Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett. 2005;389(1):12-6.
122	GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND). J Med Chem. 2002;45(8):1577-84.
123	Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels. Hum Genet. 2007;121(2):243-56.
124	Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy. 2021;17(10):2783-2799.
125	The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl). 2004;174(4):525-9.
126	High-Throughput Transcriptomics of Nontumorigenic Breast Cells Exposed to Environmentally Relevant Chemicals. Environ Health Perspect. 2024;132(4):47002.
127	Theaflavin 3, 3'-Digallate Delays Ovarian Aging by Improving Oocyte Quality and Regulating Granulosa Cell Function. Oxid Med Cell Longev. 2021;2021:7064179.
128	Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792.
129	Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry. 2007;68(5):747-53.
130	Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54(9):3206-21.
131	Establishment of a 3D multicellular placental microtissues for investigating the effect of antidepressant vortioxetine. Reprod Toxicol. 2024;123:108519.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Exogenous Modulation

Visitor Map

Correspondence